Association of Nicotine Metabolism and Sex With Relapse Following Varenicline and Nicotine Replacement Therapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Experimental and clinical psychopharmacology

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1037/pha0000141PMID 29048184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interventions to reduce harm from continued tobacco use.

  2016cited by this paper
• Gender difference and effect of pharmacotherapy: findings from a smoking cessation service

  2016cited by this paper
• Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis.

  2016cited by this paper
• The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.

  2016influential reference
• Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis

  2016cited by this paper
• Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

  2015influential reference
• Sex difference in response to varenicline for smoking cessation.

  2015cited by this paper
• An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women.

  2015cited by this paper
• [Smoking cessation: update 2015].

  2015cited by this paper
• Innovations in translational sex and gender-sensitive tobacco research.

  2015cited by this paper
• Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.

  2014cited by this paper
• Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers

  2014cited by this paper
• Smoking cessation: an update.

  2014cited by this paper
• Smoking cessation in men and women.

  2014cited by this paper
• Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review.

  2014cited by this paper
• Response to Gorelick.

  2014cited by this paper
• Ensembl 2014

  2013influential reference
• Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice.

  2013cited by this paper
• Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

  2013influential reference
• Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy.

  2013cited by this paper
• Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran.

  2012cited by this paper
• Treating Smokers in the Health Care Setting

  2012cited by this paper
• Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation.

  2011cited by this paper
• Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility

  2011cited by this paper
• Clinical practice. Treating smokers in the health care setting.

  2011cited by this paper
• Reduction versus abrupt cessation in smokers who want to quit.

  2010cited by this paper
• ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

  2010cited by this paper
• Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

  2009cited by this paper
• Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.

  2009influential reference
• Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis

  2009cited by this paper
• Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

  2008cited by this paper
• Sex differences in long-term smoking cessation rates due to nicotine patch.

  2008cited by this paper
• Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline Executive Summary

  2008cited by this paper
• ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.

  2007cited by this paper
• Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor

  2007influential reference
• Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.

  2007cited by this paper
• CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking

  2006cited by this paper
• Female sex and oral contraceptive use accelerate nicotine metabolism

  2006cited by this paper
• CYP2A6 genotype and the metabolism and disposition kinetics of nicotine

  2006cited by this paper
• Does smoking reduction increase future cessation and decrease disease risk? A qualitative review.

  2006cited by this paper
• Three haplotypes associated with CYP2A6 phenotypes in Caucasians

  2005influential reference
• Health consequences of smoking 1–4 cigarettes per day

  2005cited by this paper
• Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity

  2004cited by this paper
• Genotyping human CYP2A6 variants.

  2002cited by this paper
• Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

  2001influential reference
• A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.

  1997cited by this paper
• Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.

  1996cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper
• The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

  1991cited by this paper
• The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

  1990cited by this paper

• Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD

  2024cites this paper
• Is the nicotine metabolite ratio a useful tool to improve the effectiveness, safety, and adherence to quitting smoking? Systematic review of the literature and meta-analysis

  2024cites this paper
• The impact of rate of nicotine metabolism, as measured by the nicotine metabolite ratio (NMR), on smoking behaviours during pregnancy: A scoping review

  2024cites this paper
• The use of biomarkers to guide precision treatment for tobacco use

  2023cites this paper
• A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations

  2023influential citation
• Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial

  2023cites this paper
• "Genetic influences impacting nicotine use and abuse during adolescence: insights from human and rodent studies".

  2022cites this paper
• NCI Monograph 23. Treating Smoking in Cancer Patients: An Essential Component of Cancer Care

  2022cites this paper
• Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion

  2022cites this paper
• Tobacco Blinders: How Tobacco Control Remained Generic for Far Too Long

  2021cites this paper
• Genetic Variants in Smoking-Related Genes in Two Smoking Cessation Programs: A Cross-Sectional Study

  2021cites this paper
• Smoking Treatment: A Report Card on Progress and Challenges.

  2021cites this paper
• The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions

  2020cites this paper
• Sex- and Gender-Based Analysis in Cannabis Treatment Outcomes: A Systematic Review

  2020cites this paper